Lidoflazine and propranolol combination treatment in chronic stable angina

S. Charlap, B. Kimmel, J. Berezow, S. Molinas, J. Strom, J. Wexler, H. Willens, N. Klein, S. Pollack, W. H. Frishman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The short-term (1 month) and long-term (6 months) safety of combination lidoflazine-propranolol therapy was investigated in an open trial of 15 patients with stable angina of effort. The possible advantages of adding lidoflazine (titrated to 360 mg daily) to patients having a therapeutic response to propranolol (80-400 mg daily) was also evaluated. Effects on non-invasive indexes of left ventricular function (echocardiography, systolic time intervals, radionuclide ventriculography) and exercise tolerance (treadmill exercise testing) were determined. There was no change in mean resting heart rate with the combination therapy, although one patient developed sinus bradycardia at a rate of 44 and had to have this propranolol dose reduced. Electrocardiographic analysis showed significant prolongation of the QT(c) intervals on lidoflazine-propranolol therapy compared to propranolol alone, with 3 patients having QT(c) interval prolongation to above .53 seconds, but there was no evidence of increased arrhythmogenesis with the combination therapy compared to propranolol alone. Left ventricular end-diastolic volume index tended to rise with combination therapy. However, lidoflazine-propranolol therapy did not produce any significant effects on resting ejection fraction determined by M-mode echocardiography or by radionuclide ventriculography. Radionuclide ventriculography determined peak exercise ejection fractions were also not significantly changed with combination therapy compared to propranolol alone. There were only small, insignificant improvements in exercise tolerance with the lidoflazine-propranolol combination treatment compared to propranolol alone. It is concluded that lidoflazine-propranolol combination therapy is generally safe but has the potential of causing serious adverse effects in certain patients, i.e. those with sick sinus disease, prolonged QT(c) intervals, and severe baseline left ventricular dysfunction, and that caution must be exercised in its use. Furthermore, it would appear that combination therapy provides only slight, if any, improvements in exercise tolerance in patients with chronic stable angina having a therapeutic response to oral propranolol.

Original languageEnglish
Pages (from-to)240-252
Number of pages13
JournalAngiology
Volume36
Issue number4
StatePublished - Oct 10 1985
Externally publishedYes

Fingerprint

Lidoflazine
Stable Angina
Propranolol
Radionuclide Ventriculography
Exercise Tolerance
Therapeutics
Echocardiography
Exercise
Systole
Left Ventricular Dysfunction
Bradycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Charlap, S., Kimmel, B., Berezow, J., Molinas, S., Strom, J., Wexler, J., ... Frishman, W. H. (1985). Lidoflazine and propranolol combination treatment in chronic stable angina. Angiology, 36(4), 240-252.

Lidoflazine and propranolol combination treatment in chronic stable angina. / Charlap, S.; Kimmel, B.; Berezow, J.; Molinas, S.; Strom, J.; Wexler, J.; Willens, H.; Klein, N.; Pollack, S.; Frishman, W. H.

In: Angiology, Vol. 36, No. 4, 10.10.1985, p. 240-252.

Research output: Contribution to journalArticle

Charlap, S, Kimmel, B, Berezow, J, Molinas, S, Strom, J, Wexler, J, Willens, H, Klein, N, Pollack, S & Frishman, WH 1985, 'Lidoflazine and propranolol combination treatment in chronic stable angina', Angiology, vol. 36, no. 4, pp. 240-252.
Charlap S, Kimmel B, Berezow J, Molinas S, Strom J, Wexler J et al. Lidoflazine and propranolol combination treatment in chronic stable angina. Angiology. 1985 Oct 10;36(4):240-252.
Charlap, S. ; Kimmel, B. ; Berezow, J. ; Molinas, S. ; Strom, J. ; Wexler, J. ; Willens, H. ; Klein, N. ; Pollack, S. ; Frishman, W. H. / Lidoflazine and propranolol combination treatment in chronic stable angina. In: Angiology. 1985 ; Vol. 36, No. 4. pp. 240-252.
@article{7b200a303fcb4f85ae7efa04bd805fd7,
title = "Lidoflazine and propranolol combination treatment in chronic stable angina",
abstract = "The short-term (1 month) and long-term (6 months) safety of combination lidoflazine-propranolol therapy was investigated in an open trial of 15 patients with stable angina of effort. The possible advantages of adding lidoflazine (titrated to 360 mg daily) to patients having a therapeutic response to propranolol (80-400 mg daily) was also evaluated. Effects on non-invasive indexes of left ventricular function (echocardiography, systolic time intervals, radionuclide ventriculography) and exercise tolerance (treadmill exercise testing) were determined. There was no change in mean resting heart rate with the combination therapy, although one patient developed sinus bradycardia at a rate of 44 and had to have this propranolol dose reduced. Electrocardiographic analysis showed significant prolongation of the QT(c) intervals on lidoflazine-propranolol therapy compared to propranolol alone, with 3 patients having QT(c) interval prolongation to above .53 seconds, but there was no evidence of increased arrhythmogenesis with the combination therapy compared to propranolol alone. Left ventricular end-diastolic volume index tended to rise with combination therapy. However, lidoflazine-propranolol therapy did not produce any significant effects on resting ejection fraction determined by M-mode echocardiography or by radionuclide ventriculography. Radionuclide ventriculography determined peak exercise ejection fractions were also not significantly changed with combination therapy compared to propranolol alone. There were only small, insignificant improvements in exercise tolerance with the lidoflazine-propranolol combination treatment compared to propranolol alone. It is concluded that lidoflazine-propranolol combination therapy is generally safe but has the potential of causing serious adverse effects in certain patients, i.e. those with sick sinus disease, prolonged QT(c) intervals, and severe baseline left ventricular dysfunction, and that caution must be exercised in its use. Furthermore, it would appear that combination therapy provides only slight, if any, improvements in exercise tolerance in patients with chronic stable angina having a therapeutic response to oral propranolol.",
author = "S. Charlap and B. Kimmel and J. Berezow and S. Molinas and J. Strom and J. Wexler and H. Willens and N. Klein and S. Pollack and Frishman, {W. H.}",
year = "1985",
month = "10",
day = "10",
language = "English",
volume = "36",
pages = "240--252",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Lidoflazine and propranolol combination treatment in chronic stable angina

AU - Charlap, S.

AU - Kimmel, B.

AU - Berezow, J.

AU - Molinas, S.

AU - Strom, J.

AU - Wexler, J.

AU - Willens, H.

AU - Klein, N.

AU - Pollack, S.

AU - Frishman, W. H.

PY - 1985/10/10

Y1 - 1985/10/10

N2 - The short-term (1 month) and long-term (6 months) safety of combination lidoflazine-propranolol therapy was investigated in an open trial of 15 patients with stable angina of effort. The possible advantages of adding lidoflazine (titrated to 360 mg daily) to patients having a therapeutic response to propranolol (80-400 mg daily) was also evaluated. Effects on non-invasive indexes of left ventricular function (echocardiography, systolic time intervals, radionuclide ventriculography) and exercise tolerance (treadmill exercise testing) were determined. There was no change in mean resting heart rate with the combination therapy, although one patient developed sinus bradycardia at a rate of 44 and had to have this propranolol dose reduced. Electrocardiographic analysis showed significant prolongation of the QT(c) intervals on lidoflazine-propranolol therapy compared to propranolol alone, with 3 patients having QT(c) interval prolongation to above .53 seconds, but there was no evidence of increased arrhythmogenesis with the combination therapy compared to propranolol alone. Left ventricular end-diastolic volume index tended to rise with combination therapy. However, lidoflazine-propranolol therapy did not produce any significant effects on resting ejection fraction determined by M-mode echocardiography or by radionuclide ventriculography. Radionuclide ventriculography determined peak exercise ejection fractions were also not significantly changed with combination therapy compared to propranolol alone. There were only small, insignificant improvements in exercise tolerance with the lidoflazine-propranolol combination treatment compared to propranolol alone. It is concluded that lidoflazine-propranolol combination therapy is generally safe but has the potential of causing serious adverse effects in certain patients, i.e. those with sick sinus disease, prolonged QT(c) intervals, and severe baseline left ventricular dysfunction, and that caution must be exercised in its use. Furthermore, it would appear that combination therapy provides only slight, if any, improvements in exercise tolerance in patients with chronic stable angina having a therapeutic response to oral propranolol.

AB - The short-term (1 month) and long-term (6 months) safety of combination lidoflazine-propranolol therapy was investigated in an open trial of 15 patients with stable angina of effort. The possible advantages of adding lidoflazine (titrated to 360 mg daily) to patients having a therapeutic response to propranolol (80-400 mg daily) was also evaluated. Effects on non-invasive indexes of left ventricular function (echocardiography, systolic time intervals, radionuclide ventriculography) and exercise tolerance (treadmill exercise testing) were determined. There was no change in mean resting heart rate with the combination therapy, although one patient developed sinus bradycardia at a rate of 44 and had to have this propranolol dose reduced. Electrocardiographic analysis showed significant prolongation of the QT(c) intervals on lidoflazine-propranolol therapy compared to propranolol alone, with 3 patients having QT(c) interval prolongation to above .53 seconds, but there was no evidence of increased arrhythmogenesis with the combination therapy compared to propranolol alone. Left ventricular end-diastolic volume index tended to rise with combination therapy. However, lidoflazine-propranolol therapy did not produce any significant effects on resting ejection fraction determined by M-mode echocardiography or by radionuclide ventriculography. Radionuclide ventriculography determined peak exercise ejection fractions were also not significantly changed with combination therapy compared to propranolol alone. There were only small, insignificant improvements in exercise tolerance with the lidoflazine-propranolol combination treatment compared to propranolol alone. It is concluded that lidoflazine-propranolol combination therapy is generally safe but has the potential of causing serious adverse effects in certain patients, i.e. those with sick sinus disease, prolonged QT(c) intervals, and severe baseline left ventricular dysfunction, and that caution must be exercised in its use. Furthermore, it would appear that combination therapy provides only slight, if any, improvements in exercise tolerance in patients with chronic stable angina having a therapeutic response to oral propranolol.

UR - http://www.scopus.com/inward/record.url?scp=0021824523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021824523&partnerID=8YFLogxK

M3 - Article

C2 - 4025935

AN - SCOPUS:0021824523

VL - 36

SP - 240

EP - 252

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 4

ER -